NCT01662063View on ClinicalTrials.gov

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

PHASE3CompletedINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.

Trial Locations (79)

11201

Brooklyn

12206

Albany

14127

Orchard Park

16635

Duncansville

18015

Bethlehem

19610

Wyomissing

20902

Wheaton

21740

Hagerstown

27615

Raleigh

28210

Charlotte

28401

Wilmington

28803

Asheville

29407

Charleston

30501

Gainesville

32806

Orlando

33143

South Miami

33458

Jupiter

33614

Tampa

34233

Venice

34684

Palm Harbor

35406

Tuscaloosa

37909

Knoxville

38104

Memphis

38119

Memphis

39202

Jackson

39232

Flowood

43551

Perrysburg

43606

Toledo

45219

Cincinnati

48081

Saint Claire Shores

55121

Eagan

60053

Morton Grove

60061

Vernon Hills

62703

Springfield

63031

Florissant

63117

St Louis

63141

St Louis

67208

Wichita

68516

Lincoln

71203

Monroe

73103

Oklahoma City

73104

Oklahoma City

74135

Tulsa

77004

Houston

77058

Nassau Bay

77074

Houston

83404

Idaho Falls

83642

Meridian

83814

Coeur d'Alene

85258

Scottsdale

85381

Peoria

85704

Tucson

85715

Tucson

85723

Tucson

85724

Tucson

87102

Albuquerque

90048

Los Angeles

90606

Whittier

90806

Long Beach

91307

West Hills

91405

Van Nuys

91786

Upland

92108

San Diego

92835

Fullerton

94578

San Leandro

98104

Seattle

98502

Olympia

98801

Wenatchee

99204

Spokane

80230-7127

Denver

06606

Bridgeport

06611

Trumbull

01605

Worcester

03756

Lebanon

07012

Clifton

07728

Freehold

07726

Manalapan

08043

Voorhees Township

00716

Ponce

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY